Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan vs Pantoprazole in GERD
NCT06564246Phase 4Recruiting
- Sponsor
- Tanta University
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vonoprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Tanta University. Primary endpoint: change in the measured biomarker at 2 months. Started Sep 2024; status: recruiting.
02
Drugs
vonoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06564246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564246.